To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female patients, 18 years of age or older
Patients present with at least two of the following signs and symptom:
fever (temperature> 38c or < 36c)
heart rate > 90 beats/min)
respiratory rate> 20 breaths/min)
high white blood cell count > 12,000/ul or >10% bands)
Patient has a history of allergy or hypersensitivity (anaphylaxis) or serious adverse reaction to ertapenem or any carbapenem
Patient has a poor chance of survival for more than 14 days.
Patient has an apache ii score > 15 (see attachment 3.
Patient has an infection caused by pathogens resistant to ertapenem
The patient requires antibiotics other than ertapenem (such as: glycopeptides, macrolides or antifungal agents)